Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

INTRODUCTION: Omacetaxine mepesuccinate (omacetaxine) is a first-in-class cephalotaxine that has demonstrated efficacy in CML. In this analysis we evaluated omacetaxine in CML patients with resistance or intolerance to 2 or more tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: Data were pool...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Cortes, Jorge E., Nicolini, Franck E., Wetzler, Meir, Lipton, Jeffrey H., Akard, Luke, Craig, Adam, Nanda, Nisha, Benichou, Annie-Claude, Leonoudakis, Janis, Khoury, H. Jean, Hochhaus, Andreas, Baccarani, Michele, Kantarjian, Hagop M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775895/
https://ncbi.nlm.nih.gov/pubmed/23787123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi